The singular epidemiology of HPV infection among French Guianese women with normal cytology by Antoine Adenis et al.
RESEARCH ARTICLE Open Access
The singular epidemiology of HPV infection
among French Guianese women with
normal cytology
Antoine Adenis1, Valentin Dufit1, Maylis Douine1, Fatiha Najioullah2, Vincent Molinie3, Dominique Catherine3,
Odile Kilié2, Nadia Thomas4, Jean Luc Deshayes5, Paul Brousse6, Hatem Ben Amor6, Remy Pignoux6, Gabriel Carles7,
Claire Grenier6, Vincent Lacoste8, Raymond Cesaire2 and Mathieu Nacher1*
Abstract
Background: In French Guiana, cervical cancer is the second most frequent cancer in females. The objective of the
present study was to describe the prevalence of HPV infections in women with normal cervical cytology living in
the remote villages of French Guiana.
Methods: Before the study, the study team communicated in the remote villages on the importance of screening.
All women from the target population were offered to participate. They signed informed consent during inclusion
and then had a concomitant HPV-test and cervical smear. Only women with normal cytology and a good quality
smear were analyzed. The detection of HPV-DNA was performed using the GREINER-BIO-ONE kit.
Results: Overall, 27.2% of women with normal cervical cytology had a positive HPV-test. There was a U-shaped
evolution of prevalence with women over 50 years having the highest HPV prevalence, followed by the 20 to
29 years group. The most prevalent HPV genotypes were HPV 53(3.52%), 68(3.33%), 52(2.59%), 31(2.22%) and 16 (1.
85%). The proportion of HPV 16 among HPV-infected women was 6.8%.
Conclusions: HPV prevalence in cytologically normal women was very high. The most prevalent genotypes were
very different from what is usually described in the world, and notably in South America.
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Background
Cervical cancer is caused by the Human Papilloma
Virus. In French Guiana, the standardized incidence rate
of cervical cancer is 30.3 per 100,000 women. It is the
second most frequent cancer in females [1] and causes
significant mortality [2]. These figures show that the epi-
demiology of cervical cancer in French Guiana, a French
territory, is South American rather than French [3].
French Guiana is covered by primary forest and has a
population of 240,000 inhabitants, mostly living along
the coastline. However, part of the population lives in
the interior of French Guiana and has reduced access to
care when compared to persons living in the main cities.
Studies have shown that persons start their sexual life
early and have a greater number of sex partners than
reported in mainland France. This presumably favors the
sexual transmission of this virus [4, 5].
Vaccination against HPV is now recommended in
France, and thus in French Guiana (bivalent or tetravalent
vaccines have been commercialized since 2007) [6]. The
opportunistic screening of women aged 25–65 years is
recommended using cytological examination of cervico-
vaginal smears. In France, the HPV test is only reimbursed
when cytological examination reveals ASCUS lesions [7].
In French Guiana, efforts to conduct organized screen-
ing have been implemented in coastal areas, but not in
the interior where isolation and lack of staff make it
more difficult. Throughout the world, a number of stud-
ies have described the prevalence and risk factors of
HPV in cytologically normal women [8–12]. Several
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studies in this particular subgroup have been pooled and
have allowed to publish a meta analysis summarizing the
findings and the marked regional differences regarding
prevalence and the most prevalent genotypes [13, 14].
Chronic cervical inflammation may impair local immun-
ity and influence the relative penetrance of other HPV
genotypes than HPV 16 [13]. This target population may
thus be more suitable for global comparisons.
In French Guiana, weconducted a study between 2012
and 2014 to determine the prevalence of HPV infection
in women aged 20–65 living in the remote villages along
the border rivers between French Guiana and Suriname
or French Guiana and Brazil. Women had both a
cervical smear and an HPV test. The objective of the
present report was thus to describe the prevalence and
risk factors of HPV infections in women with normal
cervical cytology, and to compare these results with
other regions of the world.
Methods
Study population
The cross sectional study took place between December
2012 and September 2014. The study population con-
sisted of women aged 20–65 years having previously had
sexual activity living in the remote villages on the Ma-
roni and Oyapock rivers. Among these women only
those with normal cervical cytology (Bethesda 2001 cri-
teria) were included in the analysis.
Women with a history hysterectomy, pregnant women
(>3 months pregnant) were not included. Women with
abnormal cervical cytology were not included. Smears of
insufficient quality (with an absence of endocervical
cells) were excluded.
The detection of HPV DNA was performed using the
GREINER-BIO-ONE kit at the Virology laboratory in
Fort de France University Hospital. This kit allows the
identification of high risk HPV genotypes 16, 18, 31, 33,
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82 and
low risk genotypes 6, 11, 40, 42, 43, 44, 55.
Data collection
A short questionnaire was used to collect socio
economic and demographic data, and the gynecological
and obstetrical history. Vaccines against HPV being the-
oretically available since 2006 (tetravalent) or 2007(bi-
valent), all women were asked if they had been
vaccinated against HPV.
Study conduct
A study coordinator first went to the study sites to meet
the key opinion leaders, local authorities (administrative
and traditional). Communication was performed in all
villages in order to sensitize the local populations about
the public health problem of cervical cancer before
beginning the inclusion of study patients. Health center
workers were also informed and the logistical conditions
of the health centers were assessed to ensure that the
study was feasible. Three weeks before the research
started, radio messages were aired several times a day in
local languages informing the population about when
the study would take place in the village. A study coord-
inator first went to the study sites to meet the key opin-
ion leaders, local authorities. Three weeks before the
research started, radio messages were airedseveral times
a day in local languages informing the population about
when the study would take place in the village. When
the study team arrived, persons wishing to do an HPV
test and cervical cytology came to the health center. The
project was explained to them, the questionnaire was
then filled and samples were taken using the ThinPrep®
kits. Samples were stored in a cooler until the end of the
mission. The samples were then sent to Fort de France
Hospital’s Virology laboratory, in Martinique, where an
automated method was used for DNA extraction and
genotyping. Sample DNA extraction was performed
using a minimum of 2 ml in a liquid phase, followed by
PCR for amplification, and genotyping using a kit that
could discriminate between 20 genotypes, (HR and
potentially oncogenic genotypes) and identify multiple
infections.
When the HPV test was positive and when cytology
was negative, a gynecological follow up was recom-
mended to verify if HPV positivity had disappeared or if
cytological lesions had appeared.
Ethical and regulatory aspects
For study participants, the HPV test and cytology were
free of charge. All included subjects gave written
informed consent to participate in the study and for the
publication of its results. Regulatory and ethical approval
were given by the Comité d’Evaluation Ethique de l’In-
serm (CEEI), approval n° 12–064; the Comité Consultatif
sur le Traitement de l’Information en matière de
Recherche dans le domaine de la Santé (CCTIRS), n°
12.310; and the Commission Nationale de l’Informatique
et des Libertés (CNIL), n° 912,459.
Data analysis
Prevalence was obtained by dividing the number of
women with normal cytology infected by at least one
HPV genotype (high grade or low grade) by the total
number of women with normal cervical cytology. For
specific genotypes, prevalence was obtained by the num-
ber of women infected with normal cytology by that
specific genotype by the total number of women with
normal cervical cytology. The direct standardization
method was used to obtain the standardized HPV preva-
lence (using the world population as a reference
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population). The sample size required to detect a 30%
prevalence with a 5% margin of error and a 95% confi-
dence interval and an estimated population of 10,000
would be 313 persons, a figure which was exceeded.
Risk factors associated with HPV prevalence were
determined using Generalized Linear Models using the
log link and Poisson family. The Pearson goodness of fit
test was used. The data was analyzed using STATA 13
software (College Station, Texas, USA).
Results
Overall, a total of 643 women were included, of which
540 women had normal cytology. Sexual relations gener-
ally started at a young age, with 19.1% percent of the
surveyed women having had their first sexual relation
before the age of 15 years.
A large proportion (N = 147, 27.2%) of women with
normal cytology had a positive HPV test. Table one
shows a high HPV prevalence notably for the high risk
viruses. The overall age-standardized prevalence was
28.9%. Table 1 shows there was a U shaped evolution of
overall HPV prevalence by age and of high-risk-HPV
prevalence by age, with women over 50 years of age at
highest risk for HPV (40.8%), followed by the 20 to
29 years group (27.5%). Speaking Maroon languages was
associated with a greater HPV prevalence, whereas
speaking Portuguese was associated with a lower HPV
prevalence. Other risk factors such as the number of sex
partners, age at first sex, contraception use, parity, edu-
cation, or smoking were not significantly associated with
differences in HPV prevalence. None of the women de-
clared receiving the HPV vaccine.
Table 2 shows that HPV 53 and 68 were the 2 most
frequent high risk viruses. HPV16 was the 5th most fre-
quent genotype in women of all ages with normal cer-
vical cytology. However, it was the most frequent in
women aged 30–39 years with normal cervical cytology.
It seemed less frequent in women aged over 40 years.
Overall, the prevalence of HPV 16 or 18 exceeded 3%
(95% CI 2.1%–5.4%) of tested women with normal
cervical cytology. Among women with normal cytology
with any (low and high risk) HPV infection, the propor-
tion of women infected with HPV 16 was 6.8% (95% CI
3.3%–12.1%). Among women with normal cytology with
high risk HPV infection, the proportion of women in-
fected with HPV 16 was 8.7% (95% CI 4.2%–15.4%).
Overall, 115 women (21.3%) had single HPV infec-
tions, 23 (4.3%) had double infections, and 9 (1.7%) had
3 or more different HPV genotypes. Having more than
one HPV genotype was more frequent in women over
50 years of age (11/20) relative to those <= 50 (21/95)
(crude OR = 2.5 (95% CI 1–6.4), p = 0.037.
Table 3 shows multiple regression analysis models
predicting HPV positivity in women with normal
Table 1 HPV prevalence in women with normal cervical
cytology living in the remote areas of French Guiana
Proportion of women
positive for HPV
N Overall % % any HPV % HR % LR
Total 540 100.0 27.2 17.9 8.7
Age (years)
20-29 142 26.3 27.5 21.8 7.0
30-39 197 36.5 25.9 18.8 9.1
40-49 125 23.1 20.8 16.0 7.2
50-64 76 14.1 40.8 35.5 13.2
Education
Never 183 33.9 32.8 27.3 10.9
Low 173 32.0 26.0 19.1 9.2
Intermediate and high 181 33.5 21.5 16.6 5.5
Missing 3 0.6 100.0 66.7 33.3
Native language
Maroon languages 222 41.1 31.1 24.8 9.5
Amerindian languages 177 32.8 26.6 20.9 9.0
Portugueuse 98 18.1 20.4 16.3 6.1
Others 43 8.0 25.6 16.3 9.3
Age at first sexual
intercourse
< 15 103 19.1 25.2 20.4 5.8
15-17 191 35.4 24.1 18.8 6.8
>= 18 73 13.5 27.4 21.9 12.3
Missing 173 32.0 31.8 24.3 11.0
Number of sexual partners
in previous year
0 38 7.0 36.8 34.2 15.8
1 321 59.4 25.5 19.6 7.5
>=2 61 11.3 26.2 23.0 6.6
Missing 120 22.2 29.2 20.8 10.8
Parity
0-1 89 16.5 29.2 27.0 4.5
2-3 162 30.0 22.8 16.0 9.9
4-5 131 24.3 26.7 22.1 6.1
> 5 158 29.3 31.0 22.8 12.0
Contraceptives
Never 362 67.0 26.5 21.8 8.0
Oral 86 15.9 32.6 24.4 9.3
Others 92 17.0 25.0 16.3 10.9
Smoking
Yes 29 5.4 27.6 13.8 13.8
No 511 94.6 27.2 21.7 8.4
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cervical cytology. No variables significantly predicted
HPV positivity.
Discussion
The apparent variation in the relative importance of
different HPV genotypes requires further research
including studies from regions where data is lacking,
and reanalyzing existing data to better understand the
observed patterns. [13] The published studies included
in the pooled analysis and in the metaanalysis used the
international cancer research association standard meth-
odology for HPV prevalence surveys. Our sampling
design was tailored to fit the logistical constraints of the
remote villages in French Guiana. This may have intro-
duced some differences in the prevalence estimations,
but it seems unlikely that the relative frequency of differ-
ent genotypes would be affected. [13].
Overall, the observed crude and standardized (28.9%)
HPV prevalence among cytologically normal women in
this French territory was among the highest reported in
the world. It was notably much higher than in other areas
of South America (standardized prevalence = 14.3%).
However, the published reviews in the group of cytologic-
ally normal women in South America [13, 14] did not in-
volve women living in the Amazon basin which is
ethnically and socioeconomically different from Argentina
(standardized prevalence = 16.3%) [15], Chile (standard-
ized prevalence = 11.9%) [16], or Colombia (standardized
prevalence = 13.9%) [17]. Indeed a recent study in the Bra-
zilian State of Amazonas showed a very high HPV preva-
lence (crude prevalence in women with and without
cytological anomalies = 39.7%) [18]. It is also worth noting
that the mean age in women from Amazonas was 1.6 years
younger than women from French Guiana. When looking
at the most frequent genotypes, the results from rural
French Guiana were also very different from pooled re-
sults from different areas of the world. HPV 16 was only
found in 6.8% of HPV-positive women with normal cer-
vical cytology, whereas it has been reported to be around
21.4% in South America [13], 13.7% in Mexico [19], and
9.8% in Costa Rica [20], and 25.5% in Europe, 24.1% in
Canada [21], and 31.2% in the USA [13, 22]. Thus, the
prevalence of HPV 16 in French Guiana was lower than
but close to the prevalence in Mexico and Costa Rica. In
French Guiana, HPV 16 was overall the 5th most frequent
genotype whereas HPV 53 and HPV 68 were the 2 most
frequent, which is a singularity when compared to other
regions of the world where HPV 16 is the most frequent
followed by HPV 58. HPV 31 was the 4th most frequent
genotype in our study (2.2% of women with normal
cytology) and, globally, it is the 3rd most common geno-
type (0.7% of all women with normal cytology). In rural
Amazonas, where HPV prevalence was reported to be
very high [18], the most frequent HPV genotypes were
HPV 31, 68 and 53 in Macuxi and Wapishana women
(which is similar as in our study), whereas for the Yano-
mani women, it was HPV 16, 31 and 18. However, this
study included women with abnormal cytology and thus
the comparison may not be appropriate [18].
These differences may reflect epidemiologic differ-
ences in transmission chains in these remote areas
populated with ethnically homogenous populations with
little admixture. A possible explanation for these differ-
ences in small isolated populations could be the founder
effect, were a few individuals have spread these HPV
genotypes. Immunologic differences between these
ethnic groups (HLA allele frequencies in Amerindians
versus Maroons for example [23]) could also influence
the observed patterns of HPV genotypes. [24–27]
Table 2 Prevalence of different HPV genotypes in women with














No No No No %
HPV HR type
53 6 5 8 19 3.52
68 3 4 11 18 3.33
52 5 2 7 14 2.59
31 4 3 5 12 2.22
16 3 6 1 10 1.85
56 5 2 3 10 1.85
18 1 3 5 9 1.67
51 1 5 3 9 1.67
58 4 2 1 7 1.30
39 2 2 3 7 1.30
70 0 3 4 7 1.30
45 0 3 2 5 0.93
66 2 2 0 4 0.74
35 0 1 2 3 0.56
73 2 0 1 3 0.56
82 1 1 0 2 0.37
33 0 0 1 1 0.19
59 0 0 1 1 0.19
HPV LR type
44 / 55 3 9 12 24 4.44
42 3 4 3 10 1.85
6 3 4 0 7 1.30
40 1 1 3 5 0.93
43 0 0 2 2 0.37
11 0 0 1 1 0.19
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Further studies should however test this hypothesis. As
observed elsewhere [14], there was a U-shaped evolution
of HPV prevalence with women over 50 years of age
having the highest HPV prevalence, and also being more
likely to be infected by more than one HPV genotype.
However, given the early start of sexual life in this re-
gion, it is possible that HPV prevalence is also high in
women under twenty years of age, who were not sur-
veyed here.
The originality of this epidemiologic situation may
result from the very singular situation of the isolated
populations: different ancestral origins of the Maroon
and Amerindian populations living in adjacent villages,
with early sexual debut, rare sexual encounters between
Table 3 Generalized linear model analyzing potential risk factors for HPV infection in women with normal cervical cytology living in
the remote areas of French Guiana
Positive for HPV detection Positive for HPV HR type Positive for HPV LR type
No Prevalence ratioa No Prevalence ratioa No Prevalence ratioa
Age (years)
20-29 39 1.6 (0.7–3.4) 31 1.6 (0.7–3.7) 10 1.4 (0.3–5.3)
30-39 51 1.3 (0.6–2.5) 37 1.4 (0.6–3.1) 18 1.1 (0.3–3.2)
40-49 26 1 (reference) 20 1 (reference) 9 1 (reference)
50-64 31 1.9 (0.9–4.5) 27 2 (0.8–5.2) 10 1.6 (0.4–7.2)
Education
Never 60 1 (reference) 50 1 (reference) 20 1 (reference)
Low 45 1 (0.5–2.3) 33 1 (0.5–2) 16 0.8 (0.3–2.6)
Intermediate and high 39 0.7 (0.4–1.5) 30 0.7 (0.3–1.6) 10 0.4 (0.1–1.6)
Native language
Maroon languages 69 1 (0.5–2.1) 55 0.9 (0.4–2) 21 0.9 (0.2–3.7)
Amerindian languages 47 1.1 (0.5–2.3) 37 1.1 (0.5–2.4) 16 1.3 (0.3–4.6)
Portugueuse 20 1 (reference) 16 1 (reference) 6 1 (reference)
Others 11 1.2 (0.5–2.8) 7 0.7 (0.3–1.6) 4 2.4 (0.6–9.7)
Age at first sexual intercourse
< 15 26 1 (reference) 21 1 (reference) 6 1 (reference)
15-17 46 1.0 (0.6–1.8) 36 0.9 (0.5–1.6) 13 1.3 (0.5–3.5)
>= 18 20 1.2 (0.6–2.6) 16 1.1 (0.5–2.1) 9 2.8 (0.9–9)
Number of sexual partners in previous year
0 14 1 (reference) 13 1 (reference) 6 1 (reference)
1 82 0.8 (0.4–1.9) 63 0.6 (0.3–1.5) 24 0.8 (0.2–3.3)
>=2 16 1.1 (0.4–2.7) 14 0.9 (0.3–2.5) 4 1.3 (0.2–7)
Parity
0-1 26 1 (reference) 24 1 (reference) 4 1 (reference)
2-3 37 0.9 (0.4–1.7) 26 0.8 (0.4–1.6) 16 1.4 (0.3–5.6)
4-5 35 1.2 (0.6–2.4) 29 1 (0.5–2.1) 8 2 (0.5–8.5)
> 5 49 1.3 (0.6–2.7) 36 0.9 (0.4–2) 19 2.6 (0.5–12.4)
Contraceptives
Never 96 1 (reference) 79 1 (reference) 29 1 (reference)
Oral 28 1.1 (0.6–2.1) 21 1.1 (0.5–2.2) 8 1 (0.3–3.1)
Others 23 0.8 (0.4–1.7) 15 0.6 ( 0.2–1.4) 10 1.6 (0.5–4.5)
Smoking
No 139 1 (reference) 111 1 (reference) 43 1 (reference)
Yes 8 0.7 (0.3–1.9) 4 2.1 (0.5–9.3) 4 0.2 (0.1 - 0.9)
aGLM using the log link and Poisson family. Goodness of fit Pearson test >0.9 for all models
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ethnic groups, different immunological susceptibilities,
and different pools of HPV viruses. These results reem-
phasize [28] the potential interest of primary screening
using HPV testing in this region where over a quarter of
HPV positive women have normal smears and harbor
high grade HPV genotypes. This however requires au-
thorities to expand reimbursement to all targeted
women and not only those with abnormal cytology, as is
presently the case. The main HPV genotypes circulating
also suggest that vaccination coverage, which is presently
null, needs to be expanded. This implies operational
aspects, and perhaps also suggests that the tetravalent
vaccine should be replaced with the nonavalent HPV
vaccine, which covers HPV 6, 11, 16, 18, 31, 33, 45, 52,
and 58, because here HPV 52 was the third and HPV 31
the fourth most frequent high risk genotypes when
HPV16 was fifth and HPV 18 seventh most common
high risk genotypes.
Conclusions
HPV prevalence in cytologically normal women was very
high. The most prevalent genotypes were different from
what is usually described in the world, and notably in
South America beyond the Amazon basin. In a region
where cervical cancer is frequent, vaccination against
HPV and screening of women are important, but they
must be adapted to the local epidemiology and made
affordable for the populations.
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